IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells-Reference-Cited by-同舟云学术

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells

Published:2023-08-07 Issue:9 Volume:4 Page:1309-1325
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Wu Weiwei,Chia Tiongsun,Lu Jia,Li Xue,Guan Jian,Li Yaning,Fu Fenggen,Zhou Shuaixiang,Feng Ye,Deng Junjie,Zou Jia,Sun Jiya,Yao Ying,Ling Xiaomin,Wu Zhihai,Zhang Ying,Xu Jinling,Wang Feifei,Liang Xue,Wu Min,Liu Huisi,Chen Bingliang,He Kaijie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s43018-023-00612-0.pdf

Reference71 articles.

1. Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).

2. Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).

3. Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295–305 (2013).

4. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907–913 (1994).

5. Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends;Experimental & Molecular Medicine;2024-09-02

2. Advancements and challenges in immunocytokines: A new arsenal against cancer;Acta Pharmaceutica Sinica B;2024-08

3. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview;Pharmaceutics;2024-07-24

4. IL-2 based cancer immunotherapies: an evolving paradigm;Frontiers in Immunology;2024-07-24

5. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy;International Immunopharmacology;2024-07